Testosterone Side Effects in Women: What's Real and What's Just Too High a Dose

Search testosterone side effects in women and you'll find a list built to frighten you. A deepening voice. An enlarging clitoris. Hair falling out in the shower.

Those things are real, and they happen to real people. What almost nobody tells you is that they're dose-dependent, and that most of the fear attached to them comes from a population taking roughly ten times what women are prescribed.

The 2019 global consensus statement says this at the highest level of evidence it awards. At doses that approximate premenopausal physiological concentrations, testosterone is associated with mild acne and some additional body or facial hair, and not with alopecia, clitoromegaly, or voice change. The frightening version of the list is drawn from trans-masculine dosing, where serum levels run five to twenty times higher.

That doesn't mean nothing ever happens to anyone. It happened to me, at a dose I know sits above the physiologic range, and I'll tell you exactly what and how much. What it means is that severity tracks dose, and dose is the one thing you and your prescriber actually control. A voice that drops or a clitoris that grows isn't the price of admission. It's information, and it usually means the number is too high.

Here's the whole list.

The side effects you deserve to know about, all of them

This section exists because you deserve complete information before you start anything, not after you've noticed something. A good menopause specialist will walk through all of this with you proactively. If they don't, ask.

Clitoromegaly. Testosterone stimulates androgenic tissue, and the clitoris contains androgen receptors. Enlargement, ranging from barely noticeable to clearly visible, is a documented effect at any dose, though mild to moderate is most common at physiologic female doses. It is generally considered permanent once it occurs; it does not fully reverse if you stop the hormone. I have experienced this. I don't find it problematic, the nerve density in that tissue is unchanged, so if anything, increased surface area is not the worst outcome. But some women feel differently, and that is a legitimate individual response. Know this before you start.

Voice deepening. Testosterone affects the larynx. At supraphysiologic doses, as trans men on male doses routinely experience, voice changes can be dramatic and permanent. At physiologic female doses, any change is generally subtle. I've experienced mild deepening; my voice was already on the higher end and the shift is small enough that I don't notice it in daily conversation. For women in voice-dependent professions (singers, public speakers, broadcast journalists), this deserves a specific conversation about dose and monitoring.

Hair loss, and what you can actually do about it.

This one is the most complicated, so it gets more space.

The mechanism: testosterone is converted in peripheral tissues (including the scalp) into dihydrotestosterone (DHT) by an enzyme called 5-alpha reductase. DHT is approximately five times more potent than testosterone at the androgen receptor. In hair follicles that are genetically susceptible, DHT binding shortens the growth phase of the hair cycle and progressively miniaturizes follicles, turning thick terminal hairs into thin vellus hairs. This is androgenic alopecia. Not everyone gets it. Genetic predisposition determines who is vulnerable.

Risk indicators: a father with male pattern baldness, or a mother/sisters with visible female pattern thinning. If that's your family history, have a direct conversation with your prescriber before starting testosterone, take baseline photographs of your hairline and part width, and discuss monitoring frequency.

If you are susceptible, the good news is that hair loss and testosterone's systemic benefits run through different pathways, which means you can potentially protect the hair without defeating the purpose of the therapy.

Here's how:

Finasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT at the follicle level, reducing scalp DHT by roughly 60 to 70%. What it does NOT block: testosterone itself. Your testosterone still circulates. It still binds androgen receptors in your brain (supporting dopamine, drive, focus), muscle (supporting protein synthesis and strength), and bone (supporting bone formation). The benefits of testosterone largely come from testosterone directly, not from its conversion to DHT. Blocking 5-alpha reductase cuts off hair-loss risk without pulling away the floor underneath everything else. Finasteride is used off-label in postmenopausal women for female pattern hair loss at doses of 2.5 to 5 mg daily, with documented efficacy. Important note: it is contraindicated in premenopausal women who could become pregnant.

Dutasteride blocks both Type 1 and Type 2 5-alpha reductase (finasteride only blocks Type 2), reducing serum DHT by approximately 98% vs finasteride's 71%. More complete DHT suppression, same logic about preserving testosterone's direct benefits. A 3-year study found dutasteride outperformed finasteride for women under 50, with improvement in up to 80% of patients. Same pregnancy contraindication.

Minoxidil works through an entirely different pathway, vasodilation. It's a potassium channel opener that increases blood flow to hair follicles, extends the anagen (growth) phase, and stimulates growth factor production. It doesn't touch the androgen system in a clinically meaningful way at standard doses, which means it can be used alongside testosterone therapy without interfering. Low-dose oral minoxidil (0.5 to 1 mg/day for women) has shown strong results for female pattern hair loss in recent RCTs and is increasingly the preferred formulation over topical for compliance reasons.

What about spironolactone? Spironolactone is sometimes prescribed for androgen-related hair loss or acne in women, and it works, but by blocking androgen receptors throughout the body. Not just at the hair follicle. This means it blocks testosterone's action at the brain, muscle, and bone, too. It reverses exactly what you're trying to accomplish. Spironolactone is the wrong tool for women who want testosterone's cognitive and physical benefits while protecting their hair.

The practical takeaway: hair loss risk on testosterone is real, genetic, and not universal. If you're susceptible, it's manageable with finasteride, dutasteride, or minoxidil, none of which require you to give up the reason you started. This is a conversation to have with your prescriber at the outset, not after you notice your part widening.

---

The safety data is hiding in plain sight, trans men

The argument that we don't have enough safety data to support testosterone therapy in perimenopausal women deserves a direct response. Because we have more data than most people realize. We're just looking in the wrong place.

Trans men, individuals assigned female at birth who receive gender-affirming testosterone therapy, have been receiving testosterone at male doses for decades. Not physiologic female doses. Not the 50 to 100 ng/dL target range a menopause specialist is aiming for. Male doses: bringing their serum testosterone from female physiologic range (15 to 70 ng/dL) up to male physiologic range (300 to 1000 ng/dL). We're talking about five to twenty times higher than what any menopause physician is prescribing.

And we have approximately 30 to 50 years of published data on this population.

Kelly Casperson said it at the FDA hearing in July 2025, and the logic is worth sitting with:

"Testosterone has been used in women since the 1940s. Trans men receive 10 times the dose. What other drug do we have where we give people 10 times the dose for 50 years and publish it and then we're still asking if it's safe? Meanwhile, male testosterone products were approved with just six months of safety data. That is not a lack of evidence. It's a regulatory and equity failure."

So what does the data actually show?

On breast cancer: The largest published cohort is the Dutch nationwide study (de Blok et al., 2019, BMJ), which followed 1,229 trans men for up to 17 years on male-dose testosterone. Four cases of breast cancer were diagnosed. Four. The standardized incidence ratio compared to cisgender women was 0.2, one-fifth the expected rate. Not elevated. If anything, lower than background female risk. The mean testosterone level in trans men who did develop breast cancer was lower than the cohort median, suggesting the cases were not associated with higher testosterone exposure.

A 2023 systematic review confirmed: trans men have lower breast cancer risk than cisgender women and higher risk than cisgender men. The signal is not there.

On cardiovascular outcomes: A 2026 systematic review in Frontiers in Endocrinology analyzed 13 observational cohort studies covering 7,837 trans men, documenting 34 cardiovascular deaths over years of follow-up. In parallel, 13 randomized controlled trials of testosterone in cisgender women (at physiologic doses) reported no cardiovascular deaths. The cardiovascular picture at female physiologic doses, the doses we're actually discussing, is clean in the short-to-medium term data.

Known parameters to monitor in trans men on male doses: polycythemia (elevated red blood cell count), lipid profile, blood pressure. These are standard monitoring items, not surprise adverse events. They're manageable and well-characterized.

The argument structure here is straightforward: if we were worried about testosterone safety in female bodies, we have a large, long-duration, high-dose natural experiment that has been running for decades, published repeatedly in peer-reviewed literature, and it does not show the cancer or cardiovascular catastrophe that has been used to justify regulatory paralysis at physiologic female doses.

Casperson's formulation elsewhere: pellets tend to run supraphysiologic, levels in the 200 to 400 ng/dL range rather than the 50 to 100 ng/dL that most specialists target. Even this overshoot, common in the pellet world she cautions against, doesn't show the feared outcomes. The fears are not tracking the evidence.

For perimenopausal and menopausal women being offered low-dose testosterone to restore physiologic levels? We are, as Casperson put it, fighting about whether to give someone a glass of water while watching people swim safely in the ocean for fifty years.

---

So the short version, after all of that: if your voice drops or your clitoris grows, that isn't the toll the therapy charges. It's a number telling you something, and the number is adjustable.

What I'd want a woman to take from this page is that the list is knowable in advance, most of it is dose-dependent, and the one item that isn't universal (hair loss) is the one with three well-studied ways to protect against it. None of that is a reason to be casual. It's a reason to go in with your eyes open and a prescriber who'll monitor you.

I'm a medical technologist sharing my own story and my own reading of the research, not your clinician and not anybody's doctor. Take this list to someone who can look at it alongside your labs.

Sources

What the consensus actually says about side effects - Davis SR et al., Journal of Sexual Medicine 2019, the Global Consensus Position Statement on Testosterone Therapy for Women, published simultaneously in several journals: the international standard-of-care document. It is the source for the finding that at doses approximating premenopausal physiological concentrations, testosterone is associated with mild acne and body/facial hair but not with alopecia, clitoromegaly, or voice change.

The safety picture - Lincoff AM, Nissen SE et al., New England Journal of Medicine 2023, the TRAVERSE trial: testosterone did not increase major adverse cardiac events, even in men with existing cardiovascular disease. Nissen, who blocked women's testosterone in 2004 over cardiac fears, was senior author. (Trial population was men.) - de Blok CJM et al., BMJ 2019, a Dutch cohort of 1,229 trans men followed up to 17 years: breast cancer incidence was about one-fifth the expected rate for cisgender women. - Systematic review, Frontiers in Endocrinology 2026: across 13 cohorts of 7,837 trans men there were 34 cardiovascular deaths, and across 13 randomized trials in cisgender women on physiologic doses there were no cardiovascular deaths.

Protecting your hair - Verdonschot EH and Boersma IH, Indian J Dermatol Venereol Leprol 2014: over 3 years, both finasteride and dutasteride improved female androgenetic alopecia, with dutasteride edging ahead in women under 50. - Nascimento e Silva IF et al., J Am Acad Dermatol 2022 and Vano-Galvan S et al., J Am Acad Dermatol 2021: low-dose oral minoxidil for female pattern hair loss.

Incidence and reversibility figures for clitoromegaly and voice change at physiologic female doses are not cited here, because the consensus found no association to quantify and no reliable numbers appear to exist. Figures from trans-masculine cohorts are not transferable across a tenfold difference in dose, so they are deliberately not borrowed.